首页> 外文会议>International symposium on controlled release of bioactive materials;Consumer and diversified products conference >Development and evaluation of controlled release formulation of isosorbide-5-mononitrate
【24h】

Development and evaluation of controlled release formulation of isosorbide-5-mononitrate

机译:5-单硝酸异山梨酯控释制剂的研制与评价

获取原文

摘要

Isosorbide-5-mononitrate (Ismn) is the drug of choice in the treatment of prophylaxis of angina pectoris for long term use. Ismn has a much more predictive pharmacokinetic and pharmacodynamic profile in comparison to other nitrates that are in clinical use, but still the development of tolerance is a potential clinical problem. However, tolerance does not develop to Ismn when given in the form of modified release oral preparations. Therefore, the present investigation was aimed at development of once-a-day controlled release (CR) tablets of Ismn to improve the therapeutic efficacy and also the patient compliance.
机译:5-一硝酸异山梨酯(Ismn)是预防长期使用的心绞痛的治疗选择的药物。与临床上使用的其他硝酸盐相比,Ismn具有更可预测的药代动力学和药效学特征,但耐受性的发展仍然是潜在的临床问题。但是,以调释口服制剂的形式给予时,对Ismn的耐受性不会提高。因此,本研究旨在开发Ismn的每日一次控释(CR)片剂,以提高治疗效果以及患者依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号